Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy.

Objective: To report 2 cases of very low high-density lipoprotein cholesterol (HDL-C) levels associated with rosiglitazone therapy.

Case Summary: Two patients with type 2 diabetes taking rosiglitazone for glycemic control developed paradoxically low HDL-C levels during rosiglitazone therapy. In the first patient, the HDL-C level decreased from 33 to 11.

Antidepressant usage in the Canadian Forces.

This study was performed to evaluate the use of antidepressant medications among Canadian Forces (CF) members. A retrospective chart review was undertaken at seven CF bases for members who received antidepressant medications during a 6-month period. Data were collected on doses, duration, and types of antidepressant drugs, indications for therapy, and prescriber characteristics.